313 related articles for article (PubMed ID: 15821266)
1. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients.
Razonable RR
Am J Health Syst Pharm; 2005 Apr; 62(8 Suppl 1):S7-13. PubMed ID: 15821266
[TBL] [Abstract][Full Text] [Related]
2. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
Singh N
J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
6. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Kim T; Lee YM; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Jung JH; Shin S; Kim YH; Kang YA; Lee YS; Lee JH; Lee JH; Lee KH; Park SK; Han DJ; Kim SH
Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
[TBL] [Abstract][Full Text] [Related]
7. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.
Boeckh M
Transpl Infect Dis; 1999 Sep; 1(3):165-78. PubMed ID: 11428987
[TBL] [Abstract][Full Text] [Related]
8. Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
Guglieri-Lopez B; Perez-Pitarch A; Garcia-Cadenas I; Gimenez E; Barba P; Rabella N; Hernandez-Boluda JC; Fox L; Valcarcel D; Esquirol A; Ferriols-Lisart R; Sierra J; Solano C; Navarro D; Martino R; Piñana JL
Biol Blood Marrow Transplant; 2019 May; 25(5):1022-1030. PubMed ID: 30639821
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
10. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation.
Boeckh M; Fries B; Nichols WG
Pediatr Transplant; 2004 Jun; 8 Suppl 5():19-27. PubMed ID: 15125702
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of cytomegalovirus disease in transplant patients.
Uknis ME
Am J Health Syst Pharm; 2005 Apr; 62(8 Suppl 1):S3-6. PubMed ID: 15821265
[TBL] [Abstract][Full Text] [Related]
13. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
[TBL] [Abstract][Full Text] [Related]
14. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy.
Boeckh M; Nichols WG
Blood; 2004 Mar; 103(6):2003-8. PubMed ID: 14644993
[TBL] [Abstract][Full Text] [Related]
15. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy.
Mendez-Eirin E; Paniagua-Martín MJ; Marzoa-Rivas R; Barge-Caballero E; Grille-Cancela Z; Cañizares A; Naya-Leira C; Gargallo-Fernández P; Castro-Beiras A; Crespo-Leiro M
Transplant Proc; 2012 Nov; 44(9):2660-2. PubMed ID: 23146486
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
17. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
19. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.
Girmenia C; Lazzarotto T; Bonifazi F; Patriarca F; Irrera G; Ciceri F; Aversa F; Citterio F; Cillo U; Cozzi E; Gringeri E; Baldanti F; Cavallo R; Clerici P; Barosi G; Grossi P
Clin Transplant; 2019 Oct; 33(10):e13666. PubMed ID: 31310687
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
Haidar G; Boeckh M; Singh N
J Infect Dis; 2020 Mar; 221(Suppl 1):S23-S31. PubMed ID: 32134486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]